ATE135917T1 - Stabilisierte pharmaceutische zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human il-2 umfasst und verfahren zu ihrer herstellung - Google Patents

Stabilisierte pharmaceutische zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human il-2 umfasst und verfahren zu ihrer herstellung

Info

Publication number
ATE135917T1
ATE135917T1 AT92403362T AT92403362T ATE135917T1 AT E135917 T1 ATE135917 T1 AT E135917T1 AT 92403362 T AT92403362 T AT 92403362T AT 92403362 T AT92403362 T AT 92403362T AT E135917 T1 ATE135917 T1 AT E135917T1
Authority
AT
Austria
Prior art keywords
recombinant human
glycozylated
production
pharmaceutical composition
stabilized pharmaceutical
Prior art date
Application number
AT92403362T
Other languages
English (en)
Inventor
Bruno Maneglier
Bernard Voncken
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Application granted granted Critical
Publication of ATE135917T1 publication Critical patent/ATE135917T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92403362T 1991-12-12 1992-12-11 Stabilisierte pharmaceutische zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human il-2 umfasst und verfahren zu ihrer herstellung ATE135917T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9115418A FR2684878B1 (fr) 1991-12-12 1991-12-12 Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.

Publications (1)

Publication Number Publication Date
ATE135917T1 true ATE135917T1 (de) 1996-04-15

Family

ID=9419958

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92403362T ATE135917T1 (de) 1991-12-12 1992-12-11 Stabilisierte pharmaceutische zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human il-2 umfasst und verfahren zu ihrer herstellung

Country Status (18)

Country Link
US (1) US5340574A (de)
EP (1) EP0554634B1 (de)
JP (1) JP3291340B2 (de)
KR (1) KR930012023A (de)
AT (1) ATE135917T1 (de)
AU (1) AU662940B2 (de)
CA (1) CA2085142A1 (de)
DE (1) DE69209486T2 (de)
DK (1) DK0554634T3 (de)
ES (1) ES2084965T3 (de)
FR (1) FR2684878B1 (de)
GR (1) GR3019440T3 (de)
HU (1) HU218103B (de)
IL (1) IL103862A (de)
MX (1) MX9207199A (de)
RU (1) RU2107511C1 (de)
UA (1) UA26898C2 (de)
ZA (1) ZA929627B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9280798A (en) * 1997-10-03 1999-04-27 Shionogi & Co., Ltd. Process for freeze-drying proteins
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
RU2169004C1 (ru) * 1999-11-23 2001-06-20 Государственный научно-исследовательский институт особо чистых биопрепаратов Ранозаживляющая композиция
DE602004019761D1 (de) 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
JP2008501639A (ja) * 2004-04-23 2008-01-24 ノベシン リミテッド タンパク質を安定化、保護及び可溶化させるための方法及びキット
CA2611200A1 (en) * 2005-06-06 2006-12-14 Novo Nordisk A/S Stabilised il-21 compositions
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251001C (de) *
FR353150A (fr) * 1905-04-08 1905-09-04 Gerardo Caffaro Compteurs à gaz
FR452598A (fr) * 1912-12-26 1913-05-19 Lanston Monotype Corp Ltd Perfectionnements apportés aux machines servant à la composition typographique
EP0211835B1 (de) * 1984-03-28 1990-01-03 Cetus Corporation Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5204094A (en) * 1991-01-17 1993-04-20 Roussel Uclaf Treatment of pneumothorax

Also Published As

Publication number Publication date
IL103862A (en) 1997-02-18
DE69209486D1 (de) 1996-05-02
IL103862A0 (en) 1993-04-04
CA2085142A1 (fr) 1993-06-13
HUT63575A (en) 1993-09-28
FR2684878B1 (fr) 1994-02-11
AU3004192A (en) 1993-06-17
FR2684878A1 (fr) 1993-06-18
DE69209486T2 (de) 1996-09-12
RU2107511C1 (ru) 1998-03-27
MX9207199A (es) 1993-07-01
DK0554634T3 (da) 1996-07-01
JP3291340B2 (ja) 2002-06-10
ES2084965T3 (es) 1996-05-16
UA26898C2 (uk) 1999-12-29
GR3019440T3 (en) 1996-06-30
HU218103B (hu) 2000-06-28
KR930012023A (ko) 1993-07-20
HU9203925D0 (en) 1993-03-29
JPH05345728A (ja) 1993-12-27
US5340574A (en) 1994-08-23
AU662940B2 (en) 1995-09-21
EP0554634B1 (de) 1996-03-27
ZA929627B (en) 1993-12-13
EP0554634A1 (de) 1993-08-11

Similar Documents

Publication Publication Date Title
HU9302366D0 (en) Conjugates of interferons and method for producing them
HUT51254A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
CA2031430A1 (en) Process for refolding recombinantly produced tgf-.beta.-like proteins
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
NZ228754A (en) Vitamin d analogues and pharmaceutical compositions
DK1381432T3 (da) HSA-frie interferon-beta-præparater
HUT48609A (en) Process for producing kumaran derivatives and pharmaceutical compositions comprising same as active ingredient
ATE83922T1 (de) Melphalan oder melphalanhydrochlorid enthaltende pharmazeutische formulierungen sowie melphalan und melphalanhydrochlorid und verfahren zu ihrer herstellung.
IT1241997B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
EP1089968A4 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
ZA881488B (en) New pharmaceutical compositions in the form of beadlets and method
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
ATE135917T1 (de) Stabilisierte pharmaceutische zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human il-2 umfasst und verfahren zu ihrer herstellung
HUT49370A (en) Process for producing polypeptides and pharmaceutical compositions comprising same as active ingredient
HUT49598A (en) Process for producing chromone derivatives and pharmaceutical compositions comprising same as active ingredient
HUT46660A (en) Process for producing 3-alkoxy-2-amino-propyl-amines and pharmaceutical compositions comprising the same as active ingredient
HUT49369A (en) Process for producing new amino acid glycerides and pharmaceutical compositions comprising same
HUT61024A (en) Process for producing 10(1-hydroxyethyl)-11-oxo-1-aza-tricyclo/7.2.0.0.3.8/undex-2-ene-2-carboxylic acid esters and pharmaceutical compositions comprising same as active ingredient
ATA156590A (de) Mono-(2-ammonium-2-hydroxymethyl-1,3-propandiol (2r,cis)-1,2-epoxypropylphosphonat und verfahren zu dessen herstellung sowie pharmazeutische zusammensetzungen
HUT54166A (en) Process for producing 1,1-dioxocefem-4-carbothiol acid derivatives and pharmaceutical compositions comprising same as active ingredient
IL90187A0 (en) Method for treating an auto-immune disease using succinyl-acetone and pharmaceutical compositions containing the same
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
IT8721159A0 (it) Amidi di amino tioacetali ciclici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
IT8221678A0 (it) Esteri basici ad attivita'calcioantagonista, procedimenti per la loro preparazione e relative composizioni farmaceutiche.
EP0265338A3 (en) Stable therapeutical compositions based on hydrophobic vegetable oil, and process for preparing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee